Anouk Allgeier

34.4k total citations · 3 hit papers
33 papers, 19.8k citations indexed

About

Anouk Allgeier is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anouk Allgeier has authored 33 papers receiving a total of 19.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Anouk Allgeier's work include Glioma Diagnosis and Treatment (19 papers), Brain Metastases and Treatment (12 papers) and Neuropeptides and Animal Physiology (6 papers). Anouk Allgeier is often cited by papers focused on Glioma Diagnosis and Treatment (19 papers), Brain Metastases and Treatment (12 papers) and Neuropeptides and Animal Physiology (6 papers). Anouk Allgeier collaborates with scholars based in Netherlands, Belgium and France. Anouk Allgeier's co-authors include Martin J. van den Bent, Alba A. Brandes, Thierry Gorlia, Roger Stupp, Martin Taphoorn, Denis Lacombe, R.O. Mirimanoff, Michael Weller, Karl Bélanger and J. Gregory Cairncross and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Anouk Allgeier

31 papers receiving 19.5k citations

Hit Papers

Radiotherapy plus Concomitant and Adjuvant Temozolomide f... 2005 2026 2012 2019 2005 2012 2006 5.0k 10.0k 15.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
    2005 16.0k citations Roger Stupp, Warren Mason et al. New England Journal of Medicine profile →
  2. Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
    2012 804 citations Martin J. van den Bent, Alba A. Brandes et al. Journal of Clinical Oncology profile →
  3. Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
    2006 523 citations Martin J. van den Bent, Alba A. Brandes et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anouk Allgeier Netherlands 22 13.1k 6.6k 4.9k 4.1k 3.2k 33 19.8k
Barbara Fisher Canada 18 12.0k 0.9× 5.5k 0.8× 4.8k 1.0× 3.6k 0.9× 3.5k 1.1× 47 18.3k
Karl Bélanger Canada 17 11.3k 0.9× 6.0k 0.9× 4.1k 0.8× 3.8k 0.9× 3.4k 1.1× 39 17.6k
Samuel K. Ludwin Canada 35 11.0k 0.8× 7.0k 1.1× 4.0k 0.8× 3.9k 0.9× 3.1k 1.0× 78 20.4k
Jürgen Curschmann Switzerland 7 10.6k 0.8× 5.4k 0.8× 3.8k 0.8× 3.5k 0.8× 2.9k 0.9× 11 16.3k
Christine Marosi Austria 46 14.7k 1.1× 7.2k 1.1× 5.6k 1.1× 4.8k 1.2× 4.5k 1.4× 196 24.4k
Tom Mikkelsen United States 71 9.9k 0.8× 6.4k 1.0× 4.3k 0.9× 4.2k 1.0× 4.1k 1.3× 258 18.9k
Martin Taphoorn Netherlands 39 15.2k 1.2× 6.5k 1.0× 5.8k 1.2× 4.6k 1.1× 4.0k 1.2× 156 22.4k
Robert C. Janzer Switzerland 32 15.7k 1.2× 9.1k 1.4× 5.7k 1.2× 5.6k 1.3× 4.3k 1.3× 67 25.5k
Monika E. Hegi Switzerland 64 12.9k 1.0× 9.5k 1.5× 4.7k 1.0× 6.1k 1.5× 4.2k 1.3× 155 20.8k
R.O. Mirimanoff Switzerland 30 16.4k 1.3× 8.3k 1.3× 6.9k 1.4× 5.7k 1.4× 4.5k 1.4× 71 26.4k

Countries citing papers authored by Anouk Allgeier

Since Specialization
Citations

This map shows the geographic impact of Anouk Allgeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anouk Allgeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anouk Allgeier more than expected).

Fields of papers citing papers by Anouk Allgeier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anouk Allgeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anouk Allgeier. The network helps show where Anouk Allgeier may publish in the future.

Co-authorship network of co-authors of Anouk Allgeier

This figure shows the co-authorship network connecting the top 25 collaborators of Anouk Allgeier. A scholar is included among the top collaborators of Anouk Allgeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anouk Allgeier. Anouk Allgeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Habets, Esther J. J., Martin Klein, Martin Klein, et al.. (2013). Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of Neuro-Oncology. 116(1). 161–168. 72 indexed citations
2.
Bent, Martin J. van den, Alba A. Brandes, Martin Taphoorn, et al.. (2012). Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology. 31(3). 344–350. 804 indexed citations breakdown →
3.
Bent, Martin J. van den, Alba A. Brandes, Martin Taphoorn, et al.. (2012). LONG-TERM FOLLOW-UP OF EORTC 26951, A RANDOMIZED TRIAL ON ADJUVANT PCV CHEMOTHERAPY IN ANAPLASTIC OLIGODENDROGLIAL TUMORS. A REPORT OF THE EORTC BTG.. Data Archiving and Networked Services (DANS).
4.
Bent, Martin J. van den, Alba A. Brandes, Martin Taphoorn, et al.. (2012). LONG TERM FOLLOW-UP RESULTS OF EORTC 26951: A RANDOMIZED PHASE III STUDY ON ADJUVANT PCV CHEMOTHERAPY IN ANAPLASTIC OLIGODENDROGLIAL TUMORS - A REPORT OF THE EORTC BRAIN TUMOR GROUP. Neuro-Oncology. 14. 12–12.
5.
Franceschi, Enrico, Roger Stupp, Martin J. van den Bent, et al.. (2012). EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro-Oncology. 14(12). 1503–1510. 49 indexed citations
6.
Stupp, Roger, A. Tosoni, Jacoline E. C. Bromberg, et al.. (2011). Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Annals of Oncology. 22(9). 2144–2149. 31 indexed citations
7.
8.
Kouwenhoven, Mathilde C.M., Thierry Gorlia, Johan M. Kros, et al.. (2009). Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro-Oncology. 11(6). 737–746. 63 indexed citations
9.
Hildebrand, Jerzy, Thierry Gorlia, Johan M. Kros, et al.. (2008). Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). European Journal of Cancer. 44(9). 1210–1216. 33 indexed citations
10.
Gorlia, Thierry, Martin J. van den Bent, Monika E. Hegi, et al.. (2007). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. The Lancet Oncology. 9(1). 29–38. 412 indexed citations
11.
Stupp, Roger, Warren Mason, Martin J. van den Bent, et al.. (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 352(10). 987–996. 15995 indexed citations breakdown →
12.
Gorlia, Thierry, Roger Stupp, E. A. Eisenhauer, et al.. (2004). Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). Journal of Clinical Oncology. 22(14_suppl). 9599–9599. 6 indexed citations
13.
Gorlia, T., Roger Stupp, E. Eisenhauer, et al.. (2004). Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). Journal of Clinical Oncology. 22(14_suppl). 9599–9599. 2 indexed citations
14.
Bent, Martin J. van den, Alba A. Brandes, Johan Menten, et al.. (2003). Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal of Clinical Oncology. 21(13). 2525–2528. 223 indexed citations
15.
Allgeier, Anouk, MyTrang Nguyen, C. Massart, et al.. (2001). Mutation analysis of the Epac--Rap1 signaling pathway in cold thyroid follicular adenomas. European Journal of Endocrinology. 144(6). 605–610. 23 indexed citations
16.
Allgeier, Anouk, Karl‐Ludwig Laugwitz, Jacqueline Van Sande, Günter Schultz, & Jacques E. Dumont. (1997). Multiple G-protein coupling of the dog thyrotropin receptor. Molecular and Cellular Endocrinology. 127(1). 81–90. 46 indexed citations
17.
Sande, Jacqueline Van, C. Massart, Sabine Costagliola, et al.. (1996). Specific activation of the thyrotropin receptor by trypsin. Molecular and Cellular Endocrinology. 119(2). 161–168. 66 indexed citations
18.
Allgeier, Anouk, Stefan Offermanns, J. Van Sande, et al.. (1994). The human thyrotropin receptor activates G-proteins Gs and Gq/11.. Journal of Biological Chemistry. 269(19). 13733–13735. 158 indexed citations
19.
Duprez, Laurence, Jasmine Parma, Jacqueline Van Sande, et al.. (1994). Germline mutations in the thyrotropin receptor gene cause non–autoimmune autosomal dominant hyperthyroidism. Nature Genetics. 7(3). 396–401. 296 indexed citations
20.
Sande, Jacqueline Van, Anouk Allgeier, C. Massart, et al.. (1993). The human and dog 5-HT1D receptors can both activate and inhibit adenylate cyclase in transfected cells. European Journal of Pharmacology Molecular Pharmacology. 247(2). 177–184. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Fisher Breakdown of academic impact, for papers by Karl Bélanger Breakdown of academic impact, for papers by Samuel K. Ludwin Breakdown of academic impact, for papers by Jürgen Curschmann Breakdown of academic impact, for papers by Christine Marosi Breakdown of academic impact, for papers by Tom Mikkelsen Breakdown of academic impact, for papers by Martin Taphoorn Breakdown of academic impact, for papers by Robert C. Janzer Breakdown of academic impact, for papers by Monika E. Hegi Breakdown of academic impact, for papers by R.O. Mirimanoff
Rankless by CCL
2026